Erlotinib vs Satralizumab

## Erlotinib vs Satralizumab: Overview

This comparison examines the pharmacological differences between **Erlotinib** and **Satralizumab**.

## Mechanism of Action

**Erlotinib**: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

## Pharmacokinetics

**Half-life**: Erlotinib — 36 hours; Satralizumab — N/A.

## Chemical Properties

**Molecular Formula**: Erlotinib — C22H23N3O4; Satralizumab — N/A.

**Molecular Weight**: Erlotinib — 393.4380 g/mol; Satralizumab — N/A.

**Type**: Erlotinib — Small molecule; Satralizumab — Antibody.